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Summary Circulating neuron-specific enolase (NSE) and chromogranin A (CgA) were measured in 128 patients with neuroendocrine
tumours (NET) to compare their sensitivity and specificity, to investigate factors associated with elevated serum levels and to determine the
usefulness of these markers in the follow-up of NET patients. NSE (Cispack NSE, Cis Bio Intemational, Gif-sur-Yvette, France; normal <12.5
gig h1), and chromogranin A (CgA-Riact, Cis Bio Intemational, normal <100 jig 1-') were measured in 128 patients without renal insufficiency.
There were 99 patients with gastroenteropancreatic (GEP) NET, 19 with medullary thyroid carcinoma and ten with phaeochromocytoma. Fifty-
three patients with non-NET were studied as controls. Serum NSE and CgA levels were elevated in 48 (38%) and 76 (59%) of the 128 NET
patients respectively. In all groups of NET patients, CgA proved to be more sensitive than NSE. NSE and CgA had a specificity of 73°o and
68% respectively. Immunostaining for NSE was positive in three out of eight controls with elevated CgA levels, whereas immunostaining for
CgA and synaptophysin was negative in all cases. Elevated CgA levels were significantly associated with two independent parameters,
namely the presence of other secretions (P= 0.0001) and a heavy tumour burden (P= 0.001). Elevated NSE levels were exclusively
associated with poor tumour differentiation (P= 0.01). Among six patients with NET followed for 11-37 months. CgA appeared to be a better
marker of tumour evolution than NSE. We suggest that CgA ought to be the only general marker screened in NET patients.
Keywords: neuroendocrne tumours: neuron-specific enolase: chromogranin A: tumour markers
Immunohistochemical detection of neuron-specific enolase (NSE)
and chromogranin A CcA) is a Xen useful tool for the diagnosis
of neuroendocrine tumours (NNET). Methods have been developed
to measure serum NSE (Carnev et al. 1982: Prinz et al. 1983) and
CgA (O'Connor and Bernstein. 1984). Both are considered as
gaeneral markers of NET. as thev are detected in both neuroecto-
dermal or endodermal NET. NSE and CgA reflect the metabolic
and secreton- activity of tumours. respectively. and elex ated
serum levels mav haxe different meanings. In NET with eutopic
secretions. general markers may facilitate the interpretation of
hormone levels such as pancreatic peptides. and their measure-
ment may be more convenient than urinary measurements of
5-hydroxyvindolacetic acid. catecholamines and metabolites.
Furthermore. the sensitivitv of aeneral markers is higher than that
of the majority of ectopic secretions when all NET patients are
considered (Enksson et al. 1989). Finally. they may be useful for
the diagnosis and follow-up of patients in whom no hormonal
secretion can be demonstrated (Sobol et al. 1989).
NSE measurement has not been assianed a definite position in
the dexelopment of NET. except for patients w-ith small-cell lunc
carcinoma (Johnson et al. 1993). This is because the sensitivitv of
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this marker is low (Grouzmann et al. 1990: Cunninaham et al.
1992: Nobels et al. 1997). vith elevated levels in only halfofNET
patients. its specificity is low (Vinores et al. 1984: Schmechel.
1985: Kaiser et al. 1989: Body et al. 1992) and no correlation has
been demonstrated wvith the tumour burden. the prognosis or
response to therapy. CgA. a gIycoprotein found in the core of
storage vesicles. plays a major role in the storage and secretion of
several hormones and is a pre-prohormone with multiple sites of
proteolvsis (Deftos. 1991). Serum measurements of CgA in NET
patients have indicated that it may be a sensitive and specific
marker ofNET (O'Connor et al. 1986: Eriksson et al. 1988: Hsiao
et al. 1991). However. the question at issue is wvhether the CgA
level is related to the tumour burden or tumour secretors activitv
or both. Furthermore. data concerning its interest in the follow-up
of NET patients remain scarce. Finally. as CgA is exposed to
intensive proteolvtic actixvitv. the specificitv of the antibodies used
in the assay is crucial. Indeed. most ofthe immunoassays used for
CgA measurement in olved polyclonal antibodies recognizing
multiple forms ofCgA.
A recently dexveloped tu-o-site sandy ich immunoradiometric
assav. using yell-characterized monoclonal antibodies directed
against CgA. has been used (Degorce et al. 1996) in the present
study. whose aims were (1) to compare the respectixve sensitivity
and specificity of NSE and CgA. based on measurements of these
markers in 128 NET patients and 53 controls. (2) to investigate
factors related to increased serum levels ofboth markers and (3) to
determine their usefulness in the follow-up ofNET patients.
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Table 1 Charactenstics of secretions in the 128 NET pabents (number of patients)
NET NET Primary sitec Peptidic Amine Glycoprotein
type originb ecretosd
GEP FG (59) Head and neck (5) CT (4) 5-HIAA(1) aGP (1)
(99)
Lung (20) CT (4) 5-HIAA (13) aGP (9)
F. pancreas (11) Gastrin(3), VIP 5-HIAA (2) aGP (8)
(1). CT (1).
Insulin (1)
Somatostatin (1)
UFC (1)
NF. pancreas CT (1) aGP (1)
(23)
MG Ileum (24) CT (1) 5-HIAA (17) 0
HG Rectum (4) 0 5-HIAA (2) caGP (2)
Unknown CT (1) 5-HIAA (4) axGP (1)
(12)
MTC CT (17)e Catecholamines (0). ND
(19) 5-HIAA: ND
Phaeo. PTH-rp (1) Catecholamines (4) ND
(10)
aGEP, gastroenteropancreatic: MTC. medullary thyroid carcinoma; Phaeo. phaeochronmocytoma. DFG. MG, HG: foregut-, midgut-, hindgut-derived NET.
,F. clinically functioning pancreatic: NF, non-clinically functioning pancreatic NET. 'Abbreviations are given in the text (see methods). 'Two patients with positive
pentagatrin tests.
PATIENTS AND METHODS
Patients
One hundred and twentx-eight NET patients (72 males. 56 females:
mean age 53 t 14 years: range 13-77 years) referred to our institu-
tion with documented disease (mean follow-up since the diagnosis
of NET 56±70 months: range 3-306) w-ere enrolled. The histolog-
ical diagnosis was confirmed by a panel of pathologists (coordi-
nated by JCS) Ninety-nine had a gastroenteropancreatic (GEP)
NET. 19 a medullarv thyroid carcinoma (MTC) and ten a
phaeochromocy-toma. either eutopic (n =4) or ectopic (n = 6). The
99 GEP NET were classified according to their embryological
origin: 59 had foregut-derived tumours (head and neck. respiratorv
tract. upper digestixe tract and pancreas). 24 had midgut-derived
rumours (ileum and right colon), four had hindgut-derix ed tumours
(rectum) and 12 had an unknow-n primarv site. Six NET patients
xxith elevated CgA and NSE levels were followed up for months
(ranae 11-37 months), to determine the interest of both markers in
the follow-up of NET (Fiaure 1). CgA and NSE levels were
measured after hepatic chemoembolization in one other patient.
The degree of differentiation was analysed for 90 gastroen-
teropancreatic (GEP) NET according to the Warren and Gould
classification (Warren et al. 1985): 71 were well-differentiated
neuroendocrine carcinoma and 19 patients had poorly differenti-
ated or intermediate cell NET. An immunohistochemical studv
with NSE (Dako. Netherlands). CgA (Immunotech. France) and
synaptophysin (Immunotech) antibodies w-as performed in NET
patients when the morphological structure precluded an unequiV-
ocal diagnosis ofNET. Patients w-ith mixed tumours and small-cell
carcinomas were excluded.
Twenty-seven (21%c) patients were considered as haMing limited
disease. because only the primary site or lymph node metastases
were known, and 101 (79%c) as having extensive disease with distant
metastases. Conventional imaging methods. somatostatin receptor
scintigraphy in patients with GEP tumours and metaiodobenzl-
guanidine scintigraphy in patients 'ith phaeochromocytoma. were
used to stage disease. One hundred and fifteen (89%7) patients had
already undergone one (40 patients) or multiple (75 patients) treat-
ments including surgery (93 patients). chemotherapy (69 patients).
somatostatin analogue therapy (39 patients). interferon (eight
patients) and external radiotherapy (25 patients).
Fifty-three consecutive patients with malignant non-NET
tumours ofvarious primarv sites. including the testis (n =4). ovary
(n = 10). lung (n = 3). colon. rectum. stomach or pancreas (n = 17).
breast (n = 10). thyroid (n = 3). non-Hodgkin's lymphoma (n = 2)
or tumour of an unknown oMgin (n = 4 w-ere also studied as
controls. An immunohistochemical studv w-ith NSE. CgA and
synaptophysin antibodies was performed in eight control patients
with raised serum CgA levels. for '-hom tumour tissue was avail-
able. to exclude mixed tumours.
Methods
All samples A-ere collected after overnight fasting. Samples were
collected before treatment in patients A-ho receivedchemotherapy.
and before the morning, injection in patients treated with
somatostatin analogues. Patients with renal insufficiency (serum
creatinine >125 jmol 1-1) were excluded. Serum neuron-specific
enolase (NSE) (Cispack NSE. Cis Bio International. Gif-sur-
Yvette. France: normal. <12.5 jgc l-'). and chromogranin A (Cg'A:
CaA-Riact. Cis Bio International. normal <100 jgc 1-') levels A-ere
measured using the same blood sample. Chromogranin A was
measured usinc a novel two-site immunoradiometric assav
(IRMA) based on monoclonal antibodies that bind to two distinct
epitopes within the 145-245 region of CgA (Degorce et al. 1996).
The serum CgA level was 36±18 jg 1-' (median 32 ig 1-1: range
10-100 go, mg 1-l) in 100 normal individuals: a cut-off value was
fixed at 100 jg 1-l Several other markers were measured: plasma
calcitonin (CT) in MTC. phaeochromocvtoma and GEP patients
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TablIe 2 Number (percentag) of NET patients with inceased NSE and/or CgA leels and means, median and ranges as afunchon of the pnmary site
NETorigrl NSE NSE NSE CgA CgA CgA
(number) >12.5 g I-ie -dl >100z9g [1 m media,
(jg1-1) range (jg 1-') range
GEP (99)
FG: Head and neck 3/5 19.7 12.6, 12.6-34 2/5 163 163.5, 147-180
Lung 11/2 (55%) 24.8 16.7, 13.3-61.1 16/20 (80%) 2073 372, 133-13870
F. pancreas 5/11 (45%) 31.2 13.2, 13.1-79 8/11 (72%) 2586 1290, 112-9820
NF. pancreas 8J23 (35%) 28.6 25.2, 13.4-66.6 12/23 (52%) 624 196,29.4-3950
Total FG (59) 27/59 (46%) 26.0 20.0, 12.6-79 38/59 (64%) 1622 350, 112-13870
MG: Ileum (24) 4/24 (17%) 24.2 20.3, 14.7-32.9 14/24 (58%) 952 358.5, 101-5884
HG: Rectam (4) 1/4 16.5 - 2/4 169 169,148-190
Unknown (12) 7/12 (58%) 24.7 20.0, 13.1-41.5 7/12 (58%) 2090 1332, 173-9250
Total GEP (99) 39/99 (39%) 25.5 20.0, 12.6-79 61/99 (61%) 1453 363, 101-13870
MTC (19) 4/19(21%) 48.1 48.9, 14.9-79.6 9/19 (47%) 228 174, 105-474
Phaeo. (10) 5/10 (50%) 22.6 17.0, 13.3-35.1 6/10 (60%) 4435 3041,464-12800
Total (128) 48 (38%) 27.1 20.0, 12.6-79.6 76 (59%) 1561 361, 101-13870
aGEP, g MTC, meduaytyroidcarcinork Phaeo, phaeochrOMOCytoma FG, MG, HG, foregut-, midgut-, hindgutKeved NET;
F, dincally funtonig pancreatic; NF, n rn-licaly funtion pancreatic NET.
(Elsa-hCT, Cis Bio International; normal <10 pg ml-'); serum
glycoprotein hormone alpha subunit in GEP patients (aGP;
normal in men and premenopausal women <1 ng ml-': normal in
post-menopausal women <3 ng ml-') using a specific immuno-
radiometric assay (Ozturk et al, 1987); 24-h urinary 5-hydroxyin-
dolacetic acid excretion was measured using an HPLC method
(5HIAA; normal <42 jmol per 24 h) in GEP NET as well as
24-h urinary catecholamines and metabolites in patients with
phaeochromocytoma. Fmally, pancreatic peptides including
gastrin, insulin, glucagon, somatostatin (SMS) and vasoactive
intestmal peptide (VIP) were measured in patients with pancreatic
NET. Parathyroid hormone-related peptide (PITH-rp) was
measured in patients with hypercalcaemia and a low parathyroid
hormone (PTH 1-84) level, and 24-h urinary free cortisol (UFC),
somatostatin and glucagon in patients with hyperglycaemia. The
results of these hormone measurements are shown in Table 1. At
the time of the study, 90 (70%) patients had known secretions
other than NSE and CgA.
sbastuc
Relationships were sought between blood NSE and CgA levels
and patient characteristics (age, sex), tumour features (extent.
hormonal secretions, differentiation), and previous therapies
including somatostatin analogue therapy. The results of hormonal
secretion, including NSE and CgA results, were analysed as posi-
tive or negative. Furthermore, hormonal secretions were analysed
according to the type of secretion: biogenic amine, peptidic or
glycoprotein hormones. Analysis of histological differentiation
was restricted to 90 patients with GEP NET for whom data were
available.
Stepwise logistic regression analysis was used to assess the
influence of these different parameters on NSE and CgA secretory
status. Fisher's exact test was used to compare proportions,
whereas means were compared using a non-parametric test:
Wilcoxon's test orKruskal-Wallis' test when there were more than
two means.
This study was performed in accordance with local ethical rules.
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Figure 1 Evoluion of CgA, NSE and aGP in a 54-year-old woman with
progressive lver metastases of a norn-cinicaly-unctioning pancreatic NET.
tevels divided by ten, °levels below the normal vale
RESULTS
Sens 8vity and specificity
Sensi
NSE and CgA concentrations were elevated in 48 (38%) and 76
(59%) of 128 NETpatients respectively (Table 2, Figures 2 and 3).
Both serum markers were elevated in 33 (26%) patients. Elevated
CgA levels associated with normal NSE levels were found in 43
(33%) patients. Raised NSE levels associated with normal CgA
levels were found in 15 (12%) patients. Thirty-seven (29%)
patients were negative for both markers. In all groups of NET,
CgA was more frequently elevated than NSE. Elevated NSE and
CgA levels were found in 39% and 61% of patients with GEP
NET, in 21% and 47% of MTC patients, and in 50% and 60% of
phaeochromocytoma patients respectively (Table 2, Figures 2 and
3). CgA had the highest sensitivity in patients with lung and
clinically functioning pancreatic GEP NET. Mean CgA levels
were significantly different in the four main groups of patients
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Immunostaining performed in tumours from eight control patients
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Figure 2 Serum CgA concentrations in 128 patients with NET and in 53
controls with non-endocnne tumours. lndividual levels are represented by
dots; mean levels by lines. The dashed line represents the upper limit of the
normal range. The resutts are plotted loganthmically. FG. foregut-denved
NET excluding pancreatic NET: MG, midgut-derived NET: HG, hindgut-
derived NET; unknown, unknown primary site-derived NET; MTC, medullary
thyroid carcinoma
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Figure 3 Serum NSE concentrations in 128 patients with NET and in 53
controls with non-endocrine tumours. Indivdual levels are represented by
dots: mean levels by lines. The dashed line represents the upper limit of the
normal range. The results are plotted logarithmically. FG. foregut-dernved
NET excluding pancreatic NET; MG, midgut-derived NET: HG, hindgut-
denved NET: unknown, unknown primary site-derived NET: MTC. medullary
thyroid carcinoma
Factors associated with elevated NSE and CgA levels
Elevated CgA levels were found to be significantly associated with
tuo independent parameters. namely other secretions (P = 0.0001 )
and tumour burden (P = 0.001). Raised CgA serum levels were
found in 66/90 (73%7) patients with other secretions and in 10/38
(26%7) patients with no other secretion. Mean CgA levels were
found to be significantly hiaher in patients with other secretions
(1759 ± 3119 l-g 1) than patients with no other secretion
(249 ± 157 jgc 1-1) (P = 0.02). When the type of secretions were
analysed. only biogyenic amine (P = 0.0002) and peptidic (P =
0.005) secretions were found to be significantly associated with
raised CgA levels. When eutopic secretions of each type of NET
was analysed. on1v 5-HIAA levels were found to be siniificantlv
associated with raised CgA levels (P = 0.0001): catecholamine
secretion in phaeochromocytoma patients (P = 0.08) and CT secre-
tion in MTC patients (NS) were not found to be significantly asso-
ciated with raised CgA levels. Also. 68/101 (67%) patients with
extensix e disease and 8/27 (30%) patients with limited disease had
elevated plasmaCgA levels. When both parameters w-ere taken into
account in patients with limited disease. CgA had a sensitivitv of
41 %' (7/17) when other secretions were present. compared with
10% (1/10) in patients without any other known secretion.
Concerning patients with extensive disease. CgA had a sensitivitv
of 81% (59t73) when other secretions were present. compared with
36% (10/28) in patients without evidence of another secretion.
Raised NSE levels w-ere significantly associated with poor
tumour differentiation: they were found in 12/19 (63%7) patients
with poorlv differentiated or intermediate cell GEP NET.
and in 2371 (32%) patients with well-differentiated GEP NET (P
= 0.01). The other parameters studied were not significantly
associated with an elevated CrA or NSE level.
(P = 0.02): thev were low in MTC patients. higher in patients with
midgut and foregut GEP NET and highest in patients with
phaeochromocytoma. NSE had the highest sensitivity in patients
with lung NET and phaeochromocvtomas. No significant differ-
ence w-as found in mean NSE levels bets een the Xarious groups of
patients.
Specificity
NSE levels w-ere elevated in 14/53 (26%) and CgA levels in 17/53
(32%7) patients with non-NET rumours (Figures 2 and 3). NSE and
CgA had a specificity of 73% and 68%7. Cut-off values of 19 jg 1-1
forNSE and 160 jgc 1-' forCgA were associated with a specificity of
95%7. which led to a sensitivity of 19% and 38% for NSE and CgA
respectively. Essential hypertension w as found in 7/36 (19%) control
patients with normal CgA levels compared with 2/17 (12%) patients
with elevated CgA levels. In control patients. CgA % as elevated in
six digestive. five osvary. fourbreast. one lung. and one testis primary
tumour. with extensive disease in 11 of them. One colon. one
NSE and CgA in the follow-up of NET patients
(Figure 1)
In all six patients in shom a follo% -up study "as performed. at
least one other secretion w as known and measured concomitantlv.
None of these six patients were treated w-ith somatostatin
analogues during the observation period. Five of them had
progressive disease and were studied until a few months before
death. CgA levels correlated with the tumour burden and the
evolution of other secretions in four out of six patients. as illus-
trated in Figure 1. However. in one patient. despite the progression
ofthe metastatic process. a dramatic decrease was demonstrated in
CgA and also aGP levels: in another patient. the evolution ofCgA
and aGP was quite the opposite. with CgA correlated with the
evolution of tumour burden. NSE levels correlated with the evolu-
tion of the tumour burden in three of the six patients. In the three
other patients. NSE exhibited fluctuating levels (Figure 1) and was
within the normal range. even during, disease progression in two
cases. NSE levels correlated with the evolution ofother secretions
in onlv one ofthe six patients.
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After hepatic chemoembolization, a dramatic increase was
demonstrated in NSE and CgA levels remained unchanged.
DISCUSSION
CgA proved to be a more sensitive general marker of NET than
NSE with equivalent specificity. CgA and NSE had a 59% and
38% sensitivity respectively. Our results for both markers are in a
lower range than that of other reported series (Cunningham et al,
1992; Nobels et al, 1997). This may be related to the size of the
patient population studied and also to its characteristics: a high
percentage of patients had extensive disease (80%), a high
percentage had previously been teated (89%), a relatively high
proportion had no known secretions (30%) and patients with
small-cell lung carcinoma or neuroblastoma, in whom NSE is
known to be a sensitive marker, were excluded from the study. It
is noteworthy that previous treatments, including somatostatin
analogue therapy, did not influence the levels of both markers.
CgA levels were determined using a novel two-site IRMA, for the
first time in a large series of patients. The discrepancies between
ourfindings and those ofprevious studies may primarily be due to
the characteristics of our assay, compared with those of conven-
tional radioimmunoassays (RIAs) used in most studies. CgA is
highly affected by C-terminal proteolysis. Conventional RIAs are
based on polyclonal antibodies partly directed to the C-terminal
portion, and may detect both the entire CgA molecule andpeptidic
products. Our assay, which allows detection ofmolecular forms of
CgA, is based on recognition ofthe median domain, which is less
subject to proteolysis (Degorce et al, 1996). These assays may,
therefore, measure different molecular forms of CgA, but also
peptides derived from CgA proteolysis. In all groups of patients
with NET, CgA had a higher sensitivity than NSE. As previously
reported, very high levels ofCgA were found in patients with lung
and pancreatic NET and in those with phaeochromocytoma.
NSE and CgA had a comparable specificity of 73% and 68%
respectively. NSE has already been reported to have a low speci-
ficity (Vinores et al, 1984; Schmechel, 1985; Kaiser et al, 1989;
Body et al, 1992; Nobels et al, 1997). Like other authors in initial
studies (O'Connor and Bemsteir 1984: Eriksson et al. 1989), we
chose the upper threshold of the normal range of CgA to attain a
high level of specificity. Further studies of patients with normal
and benign disease will be necessary to obtain a more accurate
definition ofthe normal range ofCgA values with this new assay.
With a cut-offvalue fixed at 160gg 1-1, CgA anained a specificity
of 95% but sensitivity then fell to 38%. The control group has a
major influence on specificity results. The elevated CgA values
found in this group cannot be attnbuted to undetected mixed
tumours in the eight patients studied, as initially suggested, nor to
essential hypertension (O'Connor et al, 1989; Hsiao et al, 1991).
As patients with renal insufficiency were excluded, we postulate
that elevated CgA levels in the control group may have been
related to the effect ofstress frequently experienced by this partic-
ular population of patients with non-endocrine cancers (Cryer
et al, 1991; Deftos, 1991). The influence of stress on CgA levels
should then be evaluated in future studies.
Factors associated with elevated NSE and CgA levels in patients
with NET other than small-cell lung carcinoma, have seldom been
studied. In our study, raised NSE levels were significantly associ-
ated with porly differentiated tumours. Previous studies claimed
that NSE may reflect cell necrosis (Prinz et al, 1982; Bork et al,
1988; Kaiser et al. 1989; Schurmann et al, 1990; Cunningham et
al, 1992) rather than the tumour burden, and a large population of
necrotic cells is frequently encountered in poorly differentiated
NET. Our findings are not in support ofNSE as a direct marker of
tumour burden. In contrast, CgA was found to reflect both tumour
burden and tumour secretion, but independently. Elevated CgA
levels may, therefore, either be related to extensive or functioning
disease. As the mean CgA level differed only when the secretory
activity ofNET was taken into account and not the tumourburden,
this result further suggests that the secretory activity of NET may
be the key element influencing CgA results. Twenty-eight per cent
of patients had no other secretions but elevated CgA levels and
they mainly had extensive disease. This suggests that the clinical
interest ofCgA measurement in patients with limited disease and
no detected secretion could be limited. The question as to whether
increased CgA levels in patients with no oter known secretion
reflects undetected hormonal secretions or other mechanisms of
CgA secretion, remains unresolved.
As suggested by studies on physiological mechanisms of
secretions, only peptide- and amine vesicle-mediated exocytotic
secretions were associated with raised CgA levels, whereas
glycoprotein secretions were not (Kelly. 1985; Handwerger et al.
1987). Finally, our study demonstrated that the secretion of these
two general markers may reflect different pathophysiological
processes, as further suggested by the evolution of NSE and CgA
levels afterhepatic chemoembolization, which induced an isolated
rise in NSE levels, reflecting cell lysis.
Follow-up studies ofsix NET patients provided furtherinsights:
CgA levels were found to correlate with tumour burden in five out
of six patients. A discrepant evolution was found between the
tumour burden and CgA levels in one patient, which could be
related to an end stage loss of tumour differentiation. In contrast.
NSE demonstrated fluctuating levels in half of the patients,
precluding its use as a marker oftumourburden during follow-up.
We suggest that CgA measurement should be routinely
performed in NET patients, without highly conserved eutopic
secretion, such as in foregut-derived NET including non-
functioning pancreatic NET. In all other NET including MTC,
phaeochromocytoma, functioning pancreatic and midgut-derived
NET, data derived from CgA measurement or eutopic secretions
(CT, catecholamine, pancreatic peptide. 5-HLA) should be evalu-
ated in future studies.
In conclusion, CgA was found to be more sensitive than NSE,
was found to correlate with tumour burden and demonstrated a
better correlation with tumour burden evolution. We suggest that
CgA ought to be the only general marker routinely screened in
NET patients.
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